Innate Pharma Files Routine 6-K with SEC
Ticker: IPHYF · Form: 6-K · Filed: Sep 4, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Sep 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, regulatory-compliance, foreign-private-issuer
TL;DR
Innate Pharma filed a 6-K, standard procedure for foreign issuers. No major news.
AI Summary
Innate Pharma SA filed a Form 6-K on September 4, 2024, reporting its status as a foreign private issuer. The filing does not contain specific financial figures or operational updates but serves as a routine disclosure to the SEC.
Why It Matters
This filing indicates Innate Pharma is meeting its disclosure obligations as a foreign private issuer, which is important for investors tracking regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no new material information that would typically impact risk.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- 001-39084 (dollar_amount) — SEC File Number
- September 4, 2024 (date) — Filing Date
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Who is the filer?
The filer is Innate Pharma S.A.
When was this report filed?
The report was filed on September 4, 2024.
What is the company's principal executive office address?
The principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Does Innate Pharma file annual reports under Form 20-F?
Yes, the filing indicates that the registrant files annual reports under cover of Form 20-F.
Filing Stats: 206 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2024-09-04 06:11:45
Filing Documents
- a6k-iphx240904.htm (6-K) — 9KB
- exhibit991-240904.htm (EX-99.1) — 12KB
- 0001598599-24-000054.txt ( ) — 22KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date September 4, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive officer